Cefmetazolum [INN-Latin] en es it fr

Cefmetazolum [INN-Latin] Brand names, Cefmetazolum [INN-Latin] Analogs

Cefmetazolum [INN-Latin] Brand Names Mixture

  • No information avaliable

Cefmetazolum [INN-Latin] Chemical_Formula

C15H17N7O5S3

Cefmetazolum [INN-Latin] RX_link

No information avaliable

Cefmetazolum [INN-Latin] fda sheet

Cefmetazolum [INN-Latin] msds (material safety sheet)

Cefmetazolum_[INN-Latin] MSDS

Cefmetazolum [INN-Latin] Synthesis Reference

No information avaliable

Cefmetazolum [INN-Latin] Molecular Weight

471.538 g/mol

Cefmetazolum [INN-Latin] Melting Point

No information avaliable

Cefmetazolum [INN-Latin] H2O Solubility

94.2 mg/L

Cefmetazolum [INN-Latin] State

No information avaliable

Cefmetazolum [INN-Latin] LogP

-1.063

Cefmetazolum [INN-Latin] Dosage Forms

Solution for injection

Cefmetazolum [INN-Latin] Indication

For the treatment of infections caused by susceptible organisms.

Cefmetazolum [INN-Latin] Pharmacology

Cefmetazole is a second-generation cephalosporin. The cephalosporins are bactericidal drugs with both gram-positive and gram-negative activity. They inhibit bacterial cell wall synthesis in a way similar to the penicillins. Cefmetazole is more active than 1st-generation cephalosporins against indole-positive Proteus, Serratia, anaerobic gram-negative bacilli (including B. fragilis), and some E. coli, Klebsiella, and P. mirabilis, but is less active than cefoxitin or cefotetan against most gram-negative bacilli.

Cefmetazolum [INN-Latin] Absorption

Bioavailability is approximately 100% following intramuscular injection.

Cefmetazolum [INN-Latin] side effects and Toxicity

Oral LD50 in rats is 3,204 mg/kg. With other b-lactam antibiotics, adverse effects following overdosage have included nausea, vomiting, epigastric distress, diarrhea, and convulsions.

Cefmetazolum [INN-Latin] Patient Information

No information avaliable

Cefmetazolum [INN-Latin] Organisms Affected

Enteric bacteria and other eubacteria